Supply chain management in regenerative medicine manufacturing

  1. Lookup NU author(s)
  2. Dr Lucy Foley
  3. Professor Christian Hicks
Author(s)Hicks C; Foley LA; O'Neill P
Editor(s)Spath, D., Ilg, R., Krause, T.
Publication type Conference Proceedings (inc. Abstract)
Conference Name21st International Conference on Production Research: Innovations in Product and Production
Conference LocationStuttgart, Germany
Year of Conference2011
Source Publication Date31 July - 4 August 2011
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cell therapies may cure chronic disease, but the use of living cells as therapies raises many supply chain challenges, which are explored in this paper. There are two types of cell therapy. Allogeneic therapies are where a single donor treats many patients. Autologous therapies are where the patient supplies their own cells, which are expanded and implanted back into the patient. Most cell therapies are still manufactured in a research environment. Industrializing allogeneic treatments means scaling up production. Perhaps more challenging, autologous treatments need to be scaled out and require a service model. Lead times and quality are key which requires supply chains need to be Lean and agile. The design of supply chains for cell therapies involves establishing strategic, operational and contractual relationships; developing coordinated, robust, lean and agile processes; maintaining quality with traceability; together with fast and reliable logistics.
PublisherFraunhofer IRB Verlag
ActionsLink to this publication
Library holdingsSearch Newcastle University Library for this item